Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) had its target price cut by investment analysts at Barclays from $14.00 to $10.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 81.82% from the stock’s current price.
A number of other equities research analysts have also issued reports on the stock. Guggenheim cut their price objective on shares of Phathom Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a report on Friday, July 31st. Leerink Partners assumed coverage on shares of Phathom Pharmaceuticals in a research report on Wednesday, September 9th. They set a “market perform” rating and a $10.00 price objective on the stock. Craig Hallum reissued a “buy” rating and issued a $15.00 target price on shares of Phathom Pharmaceuticals in a report on Wednesday, October 21st. Jefferies Financial Group restated a “buy” rating and set a $16.00 target price on shares of Phathom Pharmaceuticals in a research report on Wednesday, October 14th. Finally, Citigroup restated a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.
View Our Latest Stock Analysis on Phathom Pharmaceuticals
Phathom Pharmaceuticals Price Performance
Shares of PHAT opened at $5.50 on Wednesday. The business’s 50 day moving average is $6.82 and its 200 day moving average is $9.96. Phathom Pharmaceuticals has a 12-month low of $5.01 and a 12-month high of $18.31.
Hedge Funds Weigh In On Phathom Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in PHAT. Allworth Financial LP lifted its position in Phathom Pharmaceuticals by 31.0% in the third quarter. Allworth Financial LP now owns 13,684 shares of the company’s stock worth $100,000 after buying an additional 3,241 shares during the last quarter. Entropy Technologies LP bought a new position in Phathom Pharmaceuticals during the third quarter valued at $537,000. Pathstone Holdings LLC increased its position in Phathom Pharmaceuticals by 16.7% during the third quarter. Pathstone Holdings LLC now owns 17,500 shares of the company’s stock valued at $128,000 after acquiring an additional 2,500 shares during the last quarter. Kornitzer Capital Management Inc. KS bought a new position in Phathom Pharmaceuticals during the third quarter valued at $460,000. Finally, Catalys Pacific LLC increased its position in Phathom Pharmaceuticals by 26.0% during the third quarter. Catalys Pacific LLC now owns 1,882,039 shares of the company’s stock valued at $13,739,000 after acquiring an additional 388,185 shares during the last quarter. 99.01% of the stock is owned by hedge funds and other institutional investors.
Phathom Pharmaceuticals Company Profile
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 2018, the company is based in Florham Park, New Jersey, and concentrates its commercial activities on the U.S. market. Its primary product is Voquezna (vonoprazan), an acid blocker used to treat certain conditions involving gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD. Vonoprazan is also used with antibiotics to treat Helicobacter pylori infection.
Further Reading
- Five stocks we like better than Phathom Pharmaceuticals
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
